PROKIDNEY CORP CLASS A (PROK) competitors & alternatives
Health Care · NASDAQ
PROKIDNEY CORP CLASS A (PROK)'s top competitors and alternatives — its most similar public companies — include ORGANOGENESIS HOLDINGS INC CLASS A (ORGO), DaVita (DVA), CRISPR THERAPEUTICS AG (CRSP), LINEAGE CELL THERAPEUTICS INC (LCTX), CABALETTA BIO INC (CABA), SANA BIOTECHNOLOGY INC (SANA), Lilly (Eli) (LLY), VERICEL CORP (VCEL), INTEGRA LIFESCIENCES HOLDINGS CORP (IART), SURROZEN INC (SRZN), KYVERNA THERAPEUTICS INC (KYTX) and ARTIVA BIOTHERAPEUTICS INC (ARTV). These are PROKIDNEY CORP CLASS A's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top PROK competitors & alternatives
-
ORGANOGENESIS HOLDINGS INC CLASS AORGOHealth Care
Organogenesis is a tissue-engineered wound care and surgical reconstruction company whose financial health depends critically on Medicare reimbursement rates…
$2.47 (as of 2026-07-22) · market cap $311M
-
DaVitaDVAHealth Care
Leading US dialysis and integrated kidney care provider serving end-stage renal disease patients across clinical centers, home-based settings, and transplant…
$232.08 (as of 2026-07-22) · market cap $15.0B
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
LINEAGE CELL THERAPEUTICS INCLCTXHealth Care
Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships…
$1.11 (as of 2026-07-22) · market cap $278M
-
CABALETTA BIO INCCABAHealth Care
Cabaletta Bio is a clinical-stage biotechnology firm developing one-time, curative CAR T cell therapies aimed at resetting the immune system for patients with…
$2.75 (as of 2026-07-22) · market cap $449M
-
SANA BIOTECHNOLOGY INCSANAHealth Care
Sana Biotechnology is developing ex vivo and in vivo engineered cell therapy platforms to transform the treatment of diseases like type 1 diabetes, oncology,…
$3.12 (as of 2026-07-22) · market cap $868M
-
Lilly (Eli)LLYHealth Care
A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss…
$1,163.01 (as of 2026-07-22) · market cap $1.09T
-
VERICEL CORPVCELHealth Care
Vericel is a leader in advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI for cartilage repair and…
$44.56 (as of 2026-07-22) · market cap $2.4B
-
INTEGRA LIFESCIENCES HOLDINGS CORPIARTHealth Care
Integra LifeSciences is a medical technology company specializing in regenerative medicine, neurosurgery, and advanced surgical instrumentation.
$18.82 (as of 2026-07-22) · market cap $1.5B
-
SURROZEN INCSRZNHealth Care
Surrozen is a clinical-stage biotechnology company developing regenerative therapies that harness the body's Wnt signaling pathway to repair tissue damage.
$21.72 (as of 2026-07-22) · market cap $252M
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.40 (as of 2026-07-22) · market cap $452M
-
ARTIVA BIOTHERAPEUTICS INCARTVHealth Care
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
$10.02 (as of 2026-07-22) · market cap $487M
Not quite? Describe exactly what you want →
Peers are PROKIDNEY CORP CLASS A's closest public companies by shared sub-industry, sector and business themes. See the full profile: PROKIDNEY CORP CLASS A (PROK).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.